Skip to main content
Premium Trial:

Request an Annual Quote

Tripos Stock Surges 21 Percent on Extended Pfizer Deal

NEW YORK, Nov. 15 (GenomeWeb News) - Shares in Tripos were up 21 percent at $5.46 in mid-afternoon trading as investors cheered news of an extended multimillion-dollar software license agreement with Pfizer.

The companies initially announced a wide area network partnership in January 2001 that Pfizer employ a "broad array" of Tripos' drug-discovery software tools, including the SYBYL and UNITY programs.

Details of the extended agreement were not disclosed.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.